Nagambie Resources (ASX:NAG) Increases Working Capital Facility by $1 Million
Nagambie Resources (ASX:NAG) increases its flexible working capital facility by $1M to support drilling programs at Nagambie Mine.
Tag: Regulatory News & Compliance
Industrial Minerals Limited (ASX:IND) Addresses ASX Price Query
Industrial Minerals Limited (ASX:IND) responds to ASX’s query on recent trading activity, citing increased demand for High Purity Quartz and ongoing project developments.
Guzman y Gomez Limited (ASX:GYG) Responds to ASX Compliance Inquiry on Half-Year Earnings
Guzman y Gomez Limited (ASX:GYG) confirms its half-year earnings aligned with market expectations in response to ASX compliance inquiry.
Biotron Limited (ASX:BIT) Withdraws Share Purchase Plan and Launches Rights Issue
Biotron Limited (ASX:BIT) withdraws its Share Purchase Plan and announces a $750,000 Rights Issue with Mahe Capital to secure its financial position.
Imricor Medical Systems (ASX:IMR) Submits Second FDA PMA Module
Imricor Medical Systems (ASX:IMR) submits its second FDA PMA module, advancing regulatory progress and preparing for upcoming product launches.
Kalina Power Limited (ASX:KPO) Addresses ASX’s Financial Queries
Kalina Power Limited (ASX:KPO) addresses ASX’s queries on its financial status, detailing ongoing fundraising efforts to sustain operations.
Jayride Group Limited (ASX:JAY) Launches Renounceable Entitlement Offer Amid Leadership Restructuring
Jayride Group (ASX:JAY) launches a renounceable entitlement offer to raise $4.3M and announces significant leadership changes.
New Age Exploration Limited (ASX:NAE) Requests Trading Halt
New Age Exploration Limited (ASX:NAE) requests a trading halt on the ASX pending a material capital raising announcement.
PainChek Limited (ASX:PCK) Releases Half Year Results
PainChek Limited (ASX:PCK) reports a 27% revenue increase in its half-year results, highlighting growth and expansion into the US market.
Neurotech International Ltd (ASX:NTI) Receives EMA Positive Opinion
Neurotech International Ltd (ASX:NTI) receives EMA positive opinion for NTI164 in Rett Syndrome, marking a key regulatory milestone.